

**Table 2. Characteristics of included studies – Antibioticagebruik bij acute cholecystitis**

Study	Participants	Comparison	Follow-up	Outcome measures	Comments	Risk of bias (per outcome measure)*
<i>Included in systematic review Elkasaby, 2024</i>						
Braak, 2022 PEANUTS-II trial	N at baseline Intervention: 226 Control: 231  Age (mean, SD) Intervention: 58.0 ± 13.9 years Control: 57.5 ± 14.6 years  Sex (female) Intervention: 119 (52.7%) Control: 114 (49.4%)  BMI (mean ± SD): Intervention: 28.8 ± 5.2 kg/m <sup>2</sup> Control: 28.7 ± 5.1 kg/m <sup>2</sup>	Intervention: Antibiotics (IV), preoperative  Control: Placebo	30 days after cholecystectomy	Postoperative infectious complications  Surgical site infection  Distant infections  Post-operative non-infectious complications  Mortality  Readmission  Length of hospital stay	NR	LOW

	Treatment: cholecystectomy					
Jaafar, 2020	<p>N at baseline</p> <p>Intervention: 42</p> <p>Control: 48</p> <p>Age (mean, SD)</p> <p>Intervention: 48.5 ± 24 years</p> <p>Control: 49 ± 25 years</p> <p>Sex (female)</p> <p>Intervention: 24 (57.1%)</p> <p>Control: 25 (52.1%)</p> <p>BMI (mean ± SD):</p> <p>Intervention: 27 ± 7 kg/m<sup>2</sup></p> <p>Control: 28 ± 6 kg/m<sup>2</sup></p> <p>Treatment: cholecystectomy</p>	<p>Intervention: Antibiotics (IV), preoperative</p> <p>Control: Placebo</p>	30 days postoperatively	Postoperative infectious complications	NR	Some concerns (selection of reported results)
Park, 2023	<p>N at baseline</p> <p>Intervention: 125</p>	<p>Intervention: Antibiotics (IV), preoperative</p>	4 weeks postoperatively	Postoperative infectious complications	NR	LOW

	<p>Control: 122</p> <p>Age (mean, SD)</p> <p>Intervention: 51.6 ± 15.51 years</p> <p>Control: 52.4 ± 13.71 years</p> <p>Sex (female)</p> <p>Intervention: 62 (49.6%)</p> <p>Control: 75 (61.5%)</p> <p>BMI (mean ± SD):</p> <p>Intervention: 25 ± 3.47 kg/m<sup>2</sup></p> <p>Control: 24.5 ± 3.79 kg/m<sup>2</sup></p> <p>Treatment: cholecystectomy</p>	Control: Placebo		<p>Surgical site infection</p> <p>Distant infections</p> <p>Postoperative non-infectious complications</p> <p>Mortality</p> <p>Readmission</p> <p>Length of hospital stay</p>		
Kim, 2017	<p>N at baseline</p> <p>Intervention: 93</p> <p>Control: 95</p> <p>Age (mean, SD)</p>	<p>Intervention: Antibiotics (IV), postoperative</p> <p>Control: Placebo</p>	30 days postoperatively	<p>Postoperative infectious complications</p> <p>Surgical site infection</p>	NR	LOW

	<p>Intervention: 52.1 ± 15.3 years</p> <p>Control: 52 ± 15 years</p> <p>Sex (female)</p> <p>Intervention: 44 (47.31%)</p> <p>Control: 49 (51.58%)</p> <p>BMI (mean ± SD):</p> <p>Intervention: 24.8 ± 3.4 kg/m<sup>2</sup></p> <p>Control: 25 ± 4 kg/m<sup>2</sup></p> <p>Treatment: cholecystectomy</p>			<p>Distant infections</p> <p>Postoperative non-infectious complications</p> <p>Mortality</p> <p>Length of hospital stay</p>		
Loozen, 2017	<p>N at baseline</p> <p>Intervention: 77</p> <p>Control: 73</p> <p>Age (median, IQR)</p> <p>Intervention: 52 (IQR 66) years</p> <p>Control: 54 (IQR 58) years</p>	<p>Intervention: Antibiotics (IV), postoperative</p> <p>Control: Placebo</p>	30 days after cholecystectomy	<p>Postoperative infectious complications</p> <p>Surgical site infection</p> <p>Distant infections</p>	NR	Some concerns (randomization process)

	<p>Sex (female)</p> <p>Intervention: 45 (58.4%)</p> <p>Control: 35 (48%)</p> <p>BMI (mean ± SD):</p> <p>Intervention: NR</p> <p>Control: NR</p> <p>Treatment: cholecystectomy</p>			<p>Postoperative non-infectious complications</p> <p>Mortality</p> <p>Readmission</p> <p>Length of hospital stay</p>		
Regimbeau, 2014	<p>N at baseline</p> <p>Intervention: 207</p> <p>Control: 207</p> <p>Age (median, IQR)</p> <p>Intervention: 55 (IQR 75) years</p> <p>Control: 56 (IQR 74) years</p> <p>Sex (female)</p> <p>Intervention: 107 (51.7%)</p> <p>Control: 103 (49.8%)</p>	<p>Intervention: Antibiotics (IV), postoperative</p> <p>Control: Placebo</p>	4 weeks postoperatively	<p>Postoperative infectious complications</p> <p>Surgical site infection</p> <p>Distant infections</p> <p>Postoperative non-infectious complications</p> <p>Mortality</p>	NR	Some concerns (randomization process, deviations from intended interventions)

	<p>BMI (mean ± SD):</p> <p>Intervention: NR</p> <p>Control: NR</p> <p>Treatment: cholecystectomy</p>			<p>Readmission</p> <p>Length of hospital stay</p>		
Santibanes, 2018	<p>N at baseline</p> <p>Intervention: 96</p> <p>Control: 105</p> <p>Age (mean, SD)</p> <p>Intervention: 49.9 ± 14.7 years</p> <p>Control: 49.9 ± 14.3 years</p> <p>Sex (female)</p> <p>Intervention: 44 (45.8%)</p> <p>Control: 57 (54.3%)</p> <p>BMI (mean ± SD):</p> <p>Intervention: 28.6 ± 5.2 kg/m<sup>2</sup></p> <p>Control: 28.2 ± 4.3 kg/m<sup>2</sup></p>	<p>Intervention: Antibiotics (oral), postoperative</p> <p>Control: Placebo</p>	30 days postoperative	<p>Postoperative infectious complications</p> <p>Surgical site infection</p> <p>Distant infections</p> <p>Postoperative non-infectious complications</p> <p>Mortality</p> <p>Readmission</p> <p>Length of hospital stay</p>	NR	LOW

	Treatment: cholecystectomy					
<i>Individual studies</i>						
Satheeskaran, 2023 (secondary analysis of PEANUTS-II trial)	<p>N at baseline</p> <p>Intervention: 226</p> <p>Control: 231</p> <p>Age (mean, SD)</p> <p>Intervention: 58.0 ± 13.9 years</p> <p>Control: 57.5 ± 14.6 years</p> <p>Sex (female)</p> <p>Intervention: 119 (52.7%)</p> <p>Control: 114 (49.4%)</p> <p>BMI (mean ± SD):</p> <p>Intervention: 28.8 ± 5.2 kg/m<sup>2</sup></p> <p>Control: 28.7 ± 5.1 kg/m<sup>2</sup></p> <p>Treatment: cholecystectomy</p>	<p>Intervention: Antibiotics (IV), preoperative</p> <p>Control: Placebo</p>	30 days after cholecystectomy	Cost-effectiveness	<p>The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for- profit sectors.</p> <p>No competing interests declared.</p>	LOW

Mazeh, 2012	<p>N at baseline</p> <p>Intervention: 42</p> <p>Control: 42</p> <p>Age (mean, SD)</p> <p>Intervention: 46.8 (range 25-65) years</p> <p>Control: 44.3 (range 22-69) years</p> <p>Sex (male)</p> <p>Intervention: 24 (57%)</p> <p>Control: 22 (52%)</p> <p>BMI (mean ± SD):</p> <p>NR</p> <p>Treatment: elective cholecystectomy after 6-8 weeks, conservative at first</p>	<p>Intervention: IV antibiotics</p> <p>Control: supportive treatment</p>	<p>Mean follow-up 17.1 months (range 4-28 months)</p>	<p>Surgery</p> <p>Drain placement</p> <p>Complications</p> <p>Length of hospital stay</p>	<p>NR</p>	<p>Some concerns</p>
-------------	---	--	---	---	-----------	----------------------

*\*For further details, see risk of bias table in the appendix*